Squarepoint Ops LLC increased its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 105.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 211,842 shares of the company's stock after purchasing an additional 108,719 shares during the quarter. Squarepoint Ops LLC owned 0.10% of Taysha Gene Therapies worth $366,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of TSHA. Ground Swell Capital LLC purchased a new position in Taysha Gene Therapies during the 4th quarter valued at about $25,000. Cibc World Markets Corp acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter worth about $28,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter worth about $31,000. Hsbc Holdings PLC raised its position in shares of Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock worth $36,000 after acquiring an additional 8,076 shares in the last quarter. Finally, AXQ Capital LP acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter worth about $39,000. 77.70% of the stock is owned by institutional investors and hedge funds.
Taysha Gene Therapies Price Performance
Taysha Gene Therapies stock traded down $0.04 during trading hours on Friday, hitting $2.84. The stock had a trading volume of 6,656,617 shares, compared to its average volume of 3,038,555. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The stock has a market capitalization of $609.64 million, a price-to-earnings ratio of 4.51 and a beta of 0.90. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $4.32. The stock's fifty day moving average is $2.04 and its two-hundred day moving average is $1.93.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The business had revenue of $2.30 million for the quarter, compared to the consensus estimate of $1.48 million. During the same period in the prior year, the business earned ($0.10) earnings per share. As a group, analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, major shareholder Paul B. Manning purchased 750,000 shares of the company's stock in a transaction on Friday, May 30th. The stock was bought at an average cost of $2.75 per share, for a total transaction of $2,062,500.00. Following the completion of the purchase, the insider now directly owns 2,841,704 shares of the company's stock, valued at $7,814,686. The trade was a 35.86% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.70% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Several research analysts have commented on the company. Chardan Capital lifted their price target on Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Canaccord Genuity Group lifted their price target on Taysha Gene Therapies from $9.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 price target (up previously from $6.00) on shares of Taysha Gene Therapies in a research report on Monday, June 2nd. Finally, JMP Securities lifted their price target on Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a research report on Thursday, May 29th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $7.57.
Read Our Latest Analysis on Taysha Gene Therapies
Taysha Gene Therapies Profile
(
Free Report)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Featured Articles
Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
